Serum troponin-I as a marker of fibroblast growth factor-23 (FGF-23) cardiotoxic effect, in<patients with chronic kidney disease

Таранова М. В., Милованова Л. Ю., Лысенко Л. В., Милованова С. Ю., Андросова Т. В., Зубачева Д. О., Лебедева М. В., Добросмыслов И. А., Козлов В. В., Кучиева А. М., Ли О. А., Решетников В. А.

Терапевтический архив

Т. 91, Вып. 6, С. 85-92

Опубликовано: 2019

Тип ресурса: Статья

DOI:10.26442/00403660.2019.06.000253

Аннотация:

Aim. It has been established that an increased fibroblast growth factor (FGF-23) serum levels significantly contribute to the heart and blood vessels remodeling in patients with chronic kidney disease (CKD). But the precise mechanisms of the FGF-23 cardiac effect are currently being actively studied. At the same time, it is believed that the cardiac effects of FGF-23 may be due to the increasing deficit of Klotho protein as CKD progresses. In parallel with these changes, a number of studies indicate the persistence of the detectable troponins serum levels in CKD patients, even in the absence of clear clinical manifestations of cardiovascular diseases (CVD). The aim of the study was to confirm / exclude the existence of a causal relationship between elevated FGF-23, reduced Klotho and elevated troponin-I (as the most specific troponin in CKD). Materials and methods. The study included 130 CKD stages 1-5D patients without clinically pronounced symptoms of CVD (Coronary artery disease, CC

Ключевые слова:

Chronic kidney disease; FGF-23; Klotho; Troponin-I (Tr-I)

Язык текста: Русский

ISSN: 2309-5342

Таранова М. В. Марина Владимировна 1957-

Милованова Л. Ю. Людмила Юрьевна 1973-

Лысенко Л. В. Лидия Владимировна 1937-

Милованова С. Ю. Светлана Юрьевна 1975-

Андросова Т. В. Татьяна Витальевна 1972-

Зубачева Д. О. Дарья Олеговна 1995-

Лебедева М. В. Марина Валерьевна 1966-

Добросмыслов И. А. Игорь Александрович 1962-

Козлов В. В. Василий Владимирович 1974-

Кучиева А. М. Агунда Мельцовна 1981-

Ли О. А. Ольга Александровна 1978-

Решетников В. А. Владимир Анатольевич 1960-

Taranova M. V. Marina Vladimirovna 1957-

Milovanova L. Yu. Lyudmila Yuryevna 1973-

Ly'senko L. V. Lidiya Vladimirovna 1937-

Milovanova S. Yu. Svetlana Yuryevna 1975-

Androsova T. V. Tat`yana Vitalyevna 1972-

Zubacheva D. O. Dar`ya Olegovna 1995-

Lebedeva M. V. Marina Valeryevna 1966-

Dobrosmy'slov I. A. Igor` Aleksandrovich 1962-

Kozlov V. V. Vasilij Vladimirovich 1974-

Kuchieva A. M. Agunda Meltsovna 1981-

Li O. A. Ol`ga Aleksandrovna 1978-

Reshetnikov V. A. Vladimir Anatolyevich 1960-

Serum troponin-I as a marker of fibroblast growth factor-23 (FGF-23) cardiotoxic effect, in<patients with chronic kidney disease

Текст визуальный непосредственный

Терапевтический архив

Медицинское маркетинговое агентство "МедиаМедика"

Т. 91, Вып. 6 С. 85-92

2019

Статья

Chronic kidney disease FGF-23 Klotho Troponin-I (Tr-I)

Aim. It has been established that an increased fibroblast growth factor (FGF-23) serum levels significantly contribute to the heart and blood vessels remodeling in patients with chronic kidney disease (CKD). But the precise mechanisms of the FGF-23 cardiac effect are currently being actively studied. At the same time, it is believed that the cardiac effects of FGF-23 may be due to the increasing deficit of Klotho protein as CKD progresses. In parallel with these changes, a number of studies indicate the persistence of the detectable troponins serum levels in CKD patients, even in the absence of clear clinical manifestations of cardiovascular diseases (CVD). The aim of the study was to confirm / exclude the existence of a causal relationship between elevated FGF-23, reduced Klotho and elevated troponin-I (as the most specific troponin in CKD). Materials and methods. The study included 130 CKD stages 1-5D patients without clinically pronounced symptoms of CVD (Coronary artery disease, CC